Treatment with lenalidomide, a clinically active drug used in hematologic cancers [72], restored Rho GTPase signaling in T cells, rescued LFA-1 function [71] and improved immune synapse formation between T and B-CLL cells [70]. Here, ITGAL is linked to hematopoietic and lymphoid cell neoplasm.